Drug Profile
Atorvastatin/aspirin/metoprolol/ramipril - Zydus Cadila
Latest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare; Zydus Cadila
- Developer Zydus Cadila; Zydus Lifesciences
- Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Class II antiarrhythmics; Fatty acids; Heptanoic acids; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Propanolamines; Pyrroles; Salicylates; Small molecules
- Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 07 Aug 2015 No recent reports on development identified - Phase-III for Ischaemic heart disorders in India (PO)
- 26 Mar 2010 Cadila Healthcare and Zydus Cadila complete a phase III trial in Ischaemic heart disorders in India